Purpose: Until recently the role of germline genetics in prostate cancer care was not well
defined. While important questions remain, we reviewed the current understanding of …

It is increasingly important for clinicians involved in the management of prostate cancer to
understand the relevance of heritable (germline) mutations that, for select patients, affect …

Background The goal of precision medicine in prostate cancer (PCa) is to individualize the
treatment according to the patient's germline mutation status. PCa has a very high rate of …

Simple Summary Advances in our understanding of the molecular basis of prostate cancer
have resulted in the discovery of a subset of patients harboring germline variants that places …

Abstract Background An important fraction (>/~ 10%) of men with high‐risk, localized
prostate cancer and metastatic prostate cancer carry germline (heritable) pathogenic and …

Context Germline testing (GT) is increasingly impacting prostate cancer (PCa) management
and screening, with direct effects in urology, medical oncology, and radiation oncology. The …

Background Genetic testing capability and guidelines are rapidly expanding to assess
inherited prostate cancer (PCA). Clinical genetic data from multigene testing can provide …

Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading
cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment …